CAR-Expressing Natural Killer Cells for Cancer Retargeting
Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltr...
Saved in:
Published in | Transfusion medicine and hemotherapy Vol. 46; no. 1; pp. 4 - 13 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Basel, Switzerland
S. Karger AG
01.02.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!